EGFR and non-small cell lung carcinoma: Second, our analysis did not consider the presence of compound mutations in EGFR‐mutated NSCLC, as next‐generation sequencing was approved by the Pharmaceuticals and Medical Devices Agency in Japan only in June 2019, whereas our study was conducted in September 2018.